• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Zealand Pharma Announces Appointment of David M. Kendall, M.D., as Chief Medical Officer

    6/2/22 2:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZEAL alert in real time by email

    Press Release - No. 2/2022

    Zealand Pharma Announces Appointment of David M. Kendall, M.D., as Chief Medical Officer

    • David Kendall named Zealand Pharma CMO
    • Follows Zealand Pharma's appointment of Adam Steensberg as CEO and decision to refocus strategy
    • Kendall has over 35 years of diabetes and metabolic disease experience including nearly two decades in the pharma industry



    Copenhagen, DK and Boston, MA, U.S. June 2, 2022 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the appointment of David M. Kendall, M.D., as Chief Medical Officer. Dr. Kendall most recently served as Senior Global Medical Advisor at Zealand and has more than 35 years of experience in diabetes and metabolic disease, with a broad-based career in research, education, clinical care and the pharmaceutical industry.

    "Dr. Kendall's expertise will be critical to Zealand in his new role as Chief Medical Officer, particularly as we refocus efforts on advancing our unique research and development pipeline," said Adam Steensberg, Chief Executive Officer, Zealand Pharma. "Since joining our team in 2020, David has provided invaluable expertise, giving strong medical and scientific direction for multiple clinical programs across our pipeline. We look forward to benefitting even further from his leadership as we approach multiple upcoming clinical and regulatory milestones."

    "It is an honor to take on this role during such an exciting and transformative time for Zealand," said Dr. Kendall, newly appointed Chief Medical Officer, Zealand Pharma. "I'm delighted to continue working alongside Dr. Steensberg and the rest of the management team as we refocus our efforts on advancing our clinical pipeline. We remain energized to work on the development of our novel peptide-based medicines, which we believe offer the potential to improve the lives of patients with significant unmet medical needs."

    Before joining Zealand Pharma, David held a number of senior leadership positions in clinical and academic medicine and in the biopharmaceutical industry. He has served as Chief Medical Officer for MannKind Corporation, VP - Medical Affairs and Distinguished Medical Fellow at Eli Lilly and Company and as Chief Scientific and Medical Officer for the American Diabetes Association. His clinical career included roles as both Chief of Clinical Services and Medical Director at the International Diabetes Center and as faculty at the University of Minnesota. He completed his medical and specialty training at the University of Minnesota Medical School and received his undergraduate degree at St. Olaf College.

    # # #

    About Zealand Pharma A/S

    Zealand Pharma A/S (NASDAQ:ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.

    Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in Boston, and Marlborough (MA). For more information about Zealand's business and activities, please visit http://www.zealandpharma.com.

    Forward-Looking Statements

    This press release contains "forward-looking statements", as that terms is defined in the Private Securities Litigation Reform Act of 1995, as amended, that provide Zealand Pharma's expectations or forecasts of future events regarding the research, development and commercialization of pharmaceutical products. These forward-looking statements may be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "possible," "potential," "will," "would" and other words and terms of similar meaning. You should not place undue reliance on these statements, or the scientific data presented. The reader is cautioned not to rely on these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect, and which include, but are not limited to, the occurrence of adverse safety events; risks of unexpected costs or delays; unexpected concerns that may arise from additional data, analysis or results obtained during clinical trials; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates or expansion of product labelling; failure to obtain regulatory approvals in other jurisdictions; product liability claims; and the direct and indirect impacts of the ongoing COVID-19 pandemic on our business, results of operations and financial condition. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. All such forward-looking statements speak only as of the date of this press release and are based on information available to Zealand Pharma as of the date of this release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.

    For further information, please contact:

    Zealand Pharma Investor Relations

    Maeve Conneighton

    Argot Partners

    [email protected]

    Zealand Pharma Media Relations

    David Rosen

    Argot Partners

    [email protected]



    Primary Logo

    Get the next $ZEAL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZEAL

    DatePrice TargetRatingAnalyst
    3/5/2024Buy
    Berenberg
    8/8/2023Equal-Weight
    Morgan Stanley
    11/16/2022Overweight → Equal-Weight
    Morgan Stanley
    1/11/2022Hold → Buy
    Jefferies
    More analyst ratings

    $ZEAL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zealand Pharma to participate in upcoming investor conferences in September 2025

    Press release – No. 12 / 2025 Zealand Pharma to participate in upcoming investor conferences in September 2025 Copenhagen, Denmark, August 28, 2025 - Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the company will participate in the following investor conferences in September 2025. Jefferies Swiss Healthcare Summit 2025, September 3 in Zürich Adam Lange, Vice President, Investor Relations, will host investor meetings on Wednesday, September 3. Cantor Global Healthcare Conference 2025, September 3-5 in New York Adam Steensberg, President and Chief Executive

    8/28/25 11:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

    Company announcement – No. 19 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, August 20, 2025 – Zealand Pharma A/S ("Zealand") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 20 August 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder: As of 19 August 2025, Van Herk Investments B.V. (Dutch registration no. 59055057) holds nominally 7,115,191 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 9.973% of the total share capital and 9.97

    8/20/25 4:00:00 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma Announces Financial Results for the First Half of 2025

    Company announcement – No. 18 / 2025 Zealand Pharma Announces Financial Results for the First Half of 2025Petrelintide collaboration with Roche off to a strong start, while key leadership appointments and solid financial position enable exciting next chapter for Zealand Pharma. Collaboration and license agreement with Roche to co-develop and co-commercialize petrelintide as a future foundational therapy for weight management off to a strong start, with further insight and updates expected at Roche's Pharma Day in September and Zealand Pharma's Capital Markets Day in December.Petrelintide program advancing at full speed, with ZUPREME Phase 2 trials progressing towards key milestones, and R

    8/14/25 1:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZEAL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Berenberg initiated coverage on Zealand Pharma

    Berenberg initiated coverage of Zealand Pharma with a rating of Buy

    3/5/24 7:30:01 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley resumed coverage on Zealand Pharma

    Morgan Stanley resumed coverage of Zealand Pharma with a rating of Equal-Weight

    8/8/23 7:40:54 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma downgraded by Morgan Stanley

    Morgan Stanley downgraded Zealand Pharma from Overweight to Equal-Weight

    11/16/22 9:37:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZEAL
    SEC Filings

    View All

    SEC Form 15F-12B filed by Zealand Pharma A/S

    15F-12B - Zealand Pharma A/S (0001674988) (Filer)

    9/30/22 5:24:36 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Zealand Pharma A/S

    S-8 POS - Zealand Pharma A/S (0001674988) (Filer)

    9/20/22 5:20:13 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Zealand Pharma A/S

    S-8 POS - Zealand Pharma A/S (0001674988) (Filer)

    9/20/22 5:16:47 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZEAL
    Leadership Updates

    Live Leadership Updates

    View All

    Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer

    Press release – No. 9 / 2025 Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer Steven will lead the regulatory and development strategies that position Zealand Pharma at the forefront of innovation in the management of obesity and other related complications He joins CMO David Kendall and recently appointed CSO Utpal Singh to strengthen Zealand Pharma's R&D leadership and progress its differentiated clinical pipeline of potential best-in-class peptide therapeutics Copenhagen, Denmark, May 19, 2025 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnolog

    5/19/25 9:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery

    Press release – No. 5 / 2025 Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery Utpal joins Zealand Pharma at a pivotal moment as it aims to become a leader in the management of obesity and related complications He will lead the discovery and clinical translation of peptide medicines, investing in new technologies including data and computational science Utpal to expand the global scientific team to drive Zealand Pharma's next wave of highly differentiated, innovative therapies, building on the Company's strong drug development heritage Copenhagen, Denmark, 23 April 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL)

    4/23/25 9:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers

    Company announcement – No. 40 / 2023 Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers Copenhagen, Denmark, November 30, 2023 – a Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced the appointment of pharmaceutical industry veterans Enrique Conterno and Elaine Sullivan as observers to the company's board of directors. It is expected that Enrique Conterno and Elaine Sullivan will stand for election to Zealand Pharma's board of directors at the company's 2024 Annual General Meeting. "As board observes, Enrique and Elaine collectively bring decades

    11/30/23 2:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZEAL
    Financials

    Live finance-specific insights

    View All

    Zealand Pharma Announces Financial Results for the First Half of 2025

    Company announcement – No. 18 / 2025 Zealand Pharma Announces Financial Results for the First Half of 2025Petrelintide collaboration with Roche off to a strong start, while key leadership appointments and solid financial position enable exciting next chapter for Zealand Pharma. Collaboration and license agreement with Roche to co-develop and co-commercialize petrelintide as a future foundational therapy for weight management off to a strong start, with further insight and updates expected at Roche's Pharma Day in September and Zealand Pharma's Capital Markets Day in December.Petrelintide program advancing at full speed, with ZUPREME Phase 2 trials progressing towards key milestones, and R

    8/14/25 1:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results

    Press Release – No. 11 / 2025 Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results Copenhagen, Denmark, August 7, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on August 14, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the second quarter of 2025. Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; Chief Medical Officer, David Kendall;

    8/7/25 11:30:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma increases its share capital as a result of the exercise of employee warrants

    Company announcement – No. 14 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 6, 2025 – Zealand Pharma A/S ("Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 292,508 divided into 292,508 new shares with a nominal value of DKK 1 each. The capital increase is a consequence of the exercise of warrants granted under two of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pha

    6/6/25 4:00:00 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZEAL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Zealand Pharma A/S (Amendment)

    SC 13G/A - Zealand Pharma A/S (0001674988) (Subject)

    2/14/22 12:27:01 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Zealand Pharma A/S (0001674988) (Subject)

    2/3/21 1:13:21 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care